Metoxaleno Macopharma (Methoxsalen)

Methoxsalen intercalates into DNA and, when activated by UVA light, creates cross‑links that inhibit DNA synthesis. This photochemical action suppresses excessive keratinocyte proliferation and alters local immune responses, leading to clinical improvement in targeted skin conditions.

The dosage of Metoxaleno Macopharma is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the patient’s condition, response to therapy, and any concurrent treatments. Patients should follow the prescribing clinician’s instructions precisely.

Safety data for methoxsalen in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit outweighs the risk. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Methoxsalen is a classic psoralen used with UVA (PUVA) therapy, offering a well‑established efficacy profile for psoriasis and vitiligo. Compared with newer narrow‑band UVB treatments, PUVA may achieve faster clearance in severe psoriasis but carries a higher risk of phototoxicity and long‑term skin cancer, requiring careful patient selection.

Metoxaleno Macopharma should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout its shelf life.

The preparation is intended for extracorporeal use, typically administered orally under medical supervision before scheduled UVA exposure. The exact route and timing are determined by the treating physician, who coordinates drug intake with phototherapy sessions to achieve optimal therapeutic effect.

Serious risks include severe phototoxic reactions such as blistering, Stevens‑Johnson syndrome, and increased long‑term risk of skin cancers. Ocular toxicity, including cataract formation, can occur with repeated exposure, so protective eyewear and regular eye examinations are essential.

Patients with a history of photosensitivity disorders, active skin infections, uncontrolled liver disease, or those taking other strong photosensitizing medications should avoid methoxsalen. Additionally, individuals with known hypersensitivity to psoralens or who are pregnant without clear medical justification should not use this product.